Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary Intervention [0.03%]
经皮冠状动脉介入治疗的抗血小板和抗凝治疗
Dominick J Angiolillo,Matthew J Price
Dominick J Angiolillo
Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting [0.03%]
房颤患者冠脉支架植入术的抗血小板和抗凝治疗
Mikhail S Dzeshka,Richard A Brown,Davide Capodanno et al.
Mikhail S Dzeshka et al.
Stroke prevention is the main priority in the management cascade of atrial fibrillation. Most patients require long-term oral anticoagulation (OAC) and may require percutaneous coronary intervention. Prevention of recurrent cardiac ischemia...
Fabiana Rollini,Francesco Franchi,Dominick J Angiolillo
Fabiana Rollini
Antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor is the cornerstone of treatment of patients with atherothrombotic disease manifestations. Switching between P2Y12 inhibitors occurs commonly in clinical practice for a variety...
Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention [0.03%]
PCI术后蛋白酶激活受体-1拮抗剂治疗
Pierluigi Tricoci
Pierluigi Tricoci
Thrombin is a potent platelet agonist, and protease-activated receptor-1 (PAR-1) is the main thrombin receptor in human platelets and thrombin. PAR-1 antagonism has attracted interest as a potential therapeutic target to reduce atherothromb...
Wael Sumaya,Robert F Storey
Wael Sumaya
Platelet P2Y12 receptor inhibitors are crucial in the treatment of patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Ticagrelor is a reversibly binding, potent oral P2Y12 inhibitor that also is a weak i...
Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention [0.03%]
坎格雷洛：药理学，临床数据及在经皮冠状动脉介入治疗中的作用
Matthew J Price
Matthew J Price
In clinical trials that assessed the safety and efficacy of cangrelor during percutaneous coronary intervention (PCI), cangrelor was administered as a 30-μg/kg bolus followed by a 4-μg/kg/min infusion for at least 2 hours or the duration ...
Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention [0.03%]
经皮冠状动脉介入治疗后的双重抗血小板治疗的最佳疗程
Arjun Majithia,Deepak L Bhatt
Arjun Majithia
Dual antiplatelet therapy (DAPT) is an essential component of treatment in patients with coronary artery disease treated with percutaneous coronary intervention (PCI). Recommendations for duration of DAPT after PCI should consider patient-s...
Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting [0.03%]
血小板功能检测在经皮冠状动脉介入治疗和冠状动脉旁路移植术中的作用
Lisa Gross,Dirk Sibbing
Lisa Gross
There is interindividual variability in the pharmacodynamic response to antiplatelet medications. High on-treatment platelet reactivity, reflecting a failure to achieve adequate platelet inhibition, is associated with a higher risk for thro...
Larisa H Cavallari,Aniwaa Owusu Obeng
Larisa H Cavallari
There is significant interpatient variability in clopidogrel effectiveness, which is due in part to cytochrome P450 (CYP) 2C19 genotype. Approximately 30% of individuals carry CYP2C19 loss-of-function alleles, which have been consistently s...
Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention [0.03%]
急性冠脉综合征患者经皮冠状动脉介入术中抗栓治疗以减少缺血事件发生率的研究
Freek W A Verheugt
Freek W A Verheugt
Antithrombotic therapy is essential in the prevention of periprocedural death and myocardial infarction during and after percutaneous coronary intervention. In the pathogenesis of acute coronary syndromes (ACS), both platelets and the coagu...